Abstract Number: 1799 • 2016 ACR/ARHP Annual Meeting
Smoking, Antiphospholipid Antibodies and Thrombosis in SLE
Background/Purpose: Anticardiolipin Ever smoking 411 (48.1%) Past smoking 246 (49.8%) Current smoking 165 (46.6%) Never smoking 721 (48.9%) P Value (Ever vs. Never) 0.6943…Abstract Number: 1962 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target
Background/Purpose: Treatment of the thrombotic manifestations of antiphospholipid syndrome (APS) primarily focuses on inhibiting clotting pathways. In an effort to identify upstream inflammatory targets that…Abstract Number: 1965 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients. Previously, based on…Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss. Although several tests exist to guide diagnosis of…Abstract Number: 2093 • 2016 ACR/ARHP Annual Meeting
Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Background/Purpose: Patients with autoimmune disorders are at risk for thrombotic events and antiphospholipid antibodies (aPL) are one of known markers of increased thrombotic risk. The…Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…Abstract Number: 2194 • 2015 ACR/ARHP Annual Meeting
Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Background/Purpose: Our previous data showed renal artery stenosis (RAS) is more prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive population(8%),and anticoagulation with INR>=3 was…Abstract Number: 2196 • 2015 ACR/ARHP Annual Meeting
Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE
Background/Purpose: We investigated the association between the presence of antiphospholipid antibodies (aPL) and/or lupus anticoagulant (LAC) (aPL/LAC+) and all-cause mortality among end stage renal…Abstract Number: 2197 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholip Antibodies-Positive Women According to Different Treatment Protocols: A Single Center Experience over 30 Years
Background/Purpose: Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). Risk stratification may include several demographic, clinical and serological variables. Still debated is…Abstract Number: 2200 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients ± autoimmune disorders over…Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…Abstract Number: 1752 • 2015 ACR/ARHP Annual Meeting
Characterization of Epitopes Identified with Cerebral Vasculature Injury
Background/Purpose: There is an association between natural antibodies, such as anti-phospholipid antibodies, and vasculature injury in stroke and in SLE models of systemic ischemic damage. …Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…Abstract Number: 2001 • 2015 ACR/ARHP Annual Meeting
Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome
Background/Purpose: Human leukocyte antigen (HLA)-DRB1*07:01 is one of the susceptibility alleles for antiphospholipid syndrome (APS). Recently we have reported that beta-2-glycoprotein I (b2GPI) /HLA class…Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »